Advertisement

Topics

US DOD to commence new trial with Pluristem's PLX-R18 cell therapy against ARS

05:26 EDT 18 Aug 2017 | Pharmaceutical Business Review

Pluristem Therapeutics stated that a pilot study of its PLX-R18 cell therapy will be initiated by the US Department of Defense’s (DOD) Armed Forces Radiobiology Research Institute (AFRRI), part of the Uniformed Services University of Health Sciences (USU).

Original Article: US DOD to commence new trial with Pluristem's PLX-R18 cell therapy against ARS

NEXT ARTICLE

More From BioPortfolio on "US DOD to commence new trial with Pluristem's PLX-R18 cell therapy against ARS"

Advertisement
Quick Search
Advertisement
Advertisement